Seguimiento de transacciones de insiders en los distintos mercados.
Seguimiento de transacciones de insiders en los distintos mercados.
| Suscríbase para acceder a todos los datos. | ||||||
|---|---|---|---|---|---|---|
| Compañía | Sector empresarial | Capitalización de mercado ($) | # Compras netas de insiders | Valor neto de la compra ($) | % de flotación comprada | % de acciones en manos de insiders |
|
|
Pharmaceuticals & Medical Research | Large (90.6bn) | 0 | No hay actividad | — | 0–15% |
|
|
Healthcare Services | Large (10.1bn) | 0 | No hay actividad | — | 0–15% |
| Pharmaceuticals & Medical Research | Mid (3.2bn) | 0 | No hay actividad | — | 15–50% | |
|
|
Healthcare Services | Mid (2.1bn) | 0 | No hay actividad | — | 0–15% |
|
|
Pharmaceuticals & Medical Research | Mid (2.1bn) | 0 | No hay actividad | — | 15–50% |
| Pharmaceuticals & Medical Research | Small (518.3mn) | 0 | No hay actividad | — | 15–50% | |
| Healthcare Services | Small (353.6mn) | 0 | No hay actividad | — | 0–15% | |
|
|
Healthcare Services | Micro (211.5mn) | 0 | No hay actividad | — | — |
|
|
Healthcare Services | Micro (167.9mn) | 0 | No hay actividad | — | 15–50% |
|
|
Pharmaceuticals & Medical Research | Micro (151.5mn) | 0 | No hay actividad | — | 15–50% |
|
|
Healthcare Services | Micro (118.1mn) | 0 | No hay actividad | — | 0–15% |
| Pharmaceuticals & Medical Research | Micro (101.2mn) | 0 | No hay actividad | — | 0–15% | |
|
|
Healthcare Services | Micro (60.4mn) | 0 | No hay actividad | — | 50%+ |
| Pharmaceuticals & Medical Research | Micro (50.8mn) | 0 | No hay actividad | — | 15–50% | |
|
|
Healthcare Services | Nano (42.9mn) | 0 | No hay actividad | — | 15–50% |
|
|
Pharmaceuticals & Medical Research | Nano (36.4mn) | 0 | No hay actividad | — | 15–50% |
|
|
Healthcare Services | Nano (34.4mn) | 0 | No hay actividad | — | 15–50% |
|
|
Pharmaceuticals & Medical Research | Nano (34.3mn) | 0 | No hay actividad | — | 15–50% |
|
|
Healthcare Services | Nano (32.4mn) | 0 | No hay actividad | — | 50%+ |
|
|
Pharmaceuticals & Medical Research | Nano (22.6mn) | 0 | No hay actividad | — | 15–50% |
|
|
Healthcare Services | Nano (20.9mn) | 0 | No hay actividad | — | 50%+ |
|
|
Healthcare Services | Nano (17.4mn) | 0 | No hay actividad | — | 0–15% |
|
|
Healthcare Services | Nano (17.3mn) | 0 | No hay actividad | — | 50%+ |
|
|
Pharmaceuticals & Medical Research | Nano (14.7mn) | 0 | No hay actividad | — | 15–50% |
|
|
Healthcare Services | Nano (13.3mn) | 0 | No hay actividad | — | 15–50% |
|
|
Healthcare Services | Nano (13.0mn) | 0 | No hay actividad | — | 15–50% |
|
|
Healthcare Services | Nano (12.7mn) | 0 | No hay actividad | — | 15–50% |
|
|
Pharmaceuticals & Medical Research | Nano (10.8mn) | 0 | No hay actividad | — | 15–50% |
|
|
Pharmaceuticals & Medical Research | Nano (9.7mn) | 0 | No hay actividad | — | 0–15% |
|
|
Healthcare Services | Nano (8.3mn) | 0 | No hay actividad | — | 15–50% |
|
|
Healthcare Services | Nano (3.9mn) | 0 | No hay actividad | — | 50%+ |
|
|
Pharmaceuticals & Medical Research | Nano (2.5mn) | 0 | No hay actividad | — | 15–50% |
|
|
Pharmaceuticals & Medical Research | Nano (1.1mn) | 0 | No hay actividad | — | 15–50% |
|
|
Pharmaceuticals & Medical Research | - | 0 | No hay actividad | — | 15–50% |
| Pharmaceuticals & Medical Research | - | 0 | No hay actividad | — | 15–50% | |
|
|
Pharmaceuticals & Medical Research | - | 0 | No hay actividad | — | 15–50% |
|
|
Pharmaceuticals & Medical Research | - | 0 | No hay actividad | — | 15–50% |
|
|
Pharmaceuticals & Medical Research | - | 0 | No hay actividad | — | — |
| Pharmaceuticals & Medical Research | - | 0 | No hay actividad | — | — | |
| Pharmaceuticals & Medical Research | - | 0 | No hay actividad | — | — | |
| Pharmaceuticals & Medical Research | - | 0 | No hay actividad | — | — | |
| Healthcare Services | - | 0 | No hay actividad | — | 15–50% | |
|
|
Pharmaceuticals & Medical Research | - | 0 | No hay actividad | — | — |
|
|
Pharmaceuticals & Medical Research | - | 0 | No hay actividad | — | — |
|
|
Pharmaceuticals & Medical Research | - | 0 | No hay actividad | — | 0–15% |
